- Dutch life sciences VC BioGeneration Ventures led TargED’s €21.5 million Series A extension
- Proceeds will accelerate clinical development of TargED’s first-in-class targeted thrombolytic
- Two Phase 1/2 trials being initiated across Europe and the U.S., first data expected in 2026
Utrecht, the Netherlands, December 16, 2025 – TargED Biopharmaceuticals B.V., a clinical-stage biotechnology company developing next-generation targeted treatments for thrombotic diseases, today announced the closing of a €21.5 million Series A extension financing, led by BioGeneration Ventures (BGV). The round included participation from existing investors, including Andera Partners, Fund+, Hadean Ventures, Inkef Capital, Sunstone Life Science Ventures and Curie Capital, bringing
TargED’s total Series A funding to more than €60 million.
The additional capital will support the accelerated clinical development of TargED’s lead program, TGD001, a first-in-class, targeted thrombolytic designed to treat a broad range of thrombotic events by degrading both von Willebrand factor (VWF) and fibrin. The financing enables advancement into two Phase 1/2 clinical studies, expansion of clinical trial sites across Europe and the U.S. with first data expected in 2026. In December 2025, the company reported positive Phase 1 first-in-human results for TGD001, demonstrating a favorable safety profile with no spontaneous bleeding events and exhibiting
potent thrombolytic activity. The data were presented in an oral session at the American Society of Hematology (ASH) Annual Meeting.
“This investment marks an important inflection point for TargED. We are thrilled to welcome BioGeneration Ventures to our strong syndicate and grateful for the continued confidence of all our existing investors,” said Kristof Vercruysse, Chief Executive Officer of TargED Biopharmaceuticals. “The momentum behind TGD001 continues to build — from compelling preclinical data to encouraging first clinical use — and this financing enables us to move decisively into the next stage of development. We believe TGD001 has the potential to fundamentally reshape the treatment of thrombosis, offering a novel approach to universally dissolving clots across multiple life-threatening indications.”
“We are delighted to partner with TargED as it has been remarkable to watch their evolution into a leading clinical-stage company in targeted thrombolysis,” said Rianne Ellenbroek, Principal at BioGeneration Ventures. “The team has consistently executed with focus, scientific rigor, and speed, transforming a bold academic concept into a highly differentiated clinical asset. Leading this Series A extension reflects our deep conviction in both TGD001’s potential to redefine how thrombotic diseases are treated and in TargED’s ability to deliver on that promise.”
Investor Syndicate
TargED’s investor base includes Andera Partners, BioGeneration Ventures, Fund+, Hadean Ventures, Inkef Capital, Sunstone Life Science Ventures, Curie Capital, FIRST, and Utrecht Health Seed Fund.